CN116969937A - Bcl-2抑制剂 - Google Patents

Bcl-2抑制剂 Download PDF

Info

Publication number
CN116969937A
CN116969937A CN202310560508.6A CN202310560508A CN116969937A CN 116969937 A CN116969937 A CN 116969937A CN 202310560508 A CN202310560508 A CN 202310560508A CN 116969937 A CN116969937 A CN 116969937A
Authority
CN
China
Prior art keywords
azaspiro
isopropylphenyl
nonane
butyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310560508.6A
Other languages
English (en)
Chinese (zh)
Inventor
薛海
郭运行
王志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beigene Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN116969937A publication Critical patent/CN116969937A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202310560508.6A 2020-04-15 2021-04-14 Bcl-2抑制剂 Pending CN116969937A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
CN2020084992 2020-04-15
CNPCT/CN2020/084992 2020-04-15
CN2020100472 2020-07-06
CNPCT/CN2020/100472 2020-07-06
CNPCT/CN2020/125580 2020-10-30
CN2020125580 2020-10-30
CNPCT/CN2021/075831 2021-02-07
CN2021075831 2021-02-07
CN2021086189 2021-04-09
CNPCT/CN2021/086189 2021-04-09
PCT/CN2021/087225 WO2021208963A1 (en) 2020-04-15 2021-04-14 Bcl-2 inhibitor
CN202180029718.1A CN116802179A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180029718.1A Division CN116802179A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂

Publications (1)

Publication Number Publication Date
CN116969937A true CN116969937A (zh) 2023-10-31

Family

ID=78083530

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310560508.6A Pending CN116969937A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂
CN202180029718.1A Pending CN116802179A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂
CN202310559385.4A Pending CN116969936A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202180029718.1A Pending CN116802179A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂
CN202310559385.4A Pending CN116969936A (zh) 2020-04-15 2021-04-14 Bcl-2抑制剂

Country Status (13)

Country Link
US (1) US20230159522A1 (de)
EP (1) EP4136084A4 (de)
JP (1) JP2023520843A (de)
KR (1) KR20230002419A (de)
CN (3) CN116969937A (de)
AU (1) AU2021256580A1 (de)
BR (1) BR112022019525A2 (de)
CA (1) CA3172478A1 (de)
IL (1) IL296582A (de)
MX (1) MX2022013006A (de)
TW (1) TW202200574A (de)
WO (1) WO2021208963A1 (de)
ZA (1) ZA202209891B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
WO2023088167A1 (en) * 2021-11-20 2023-05-25 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
WO2023104043A1 (zh) * 2021-12-06 2023-06-15 杭州和正医药有限公司 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
WO2023122000A1 (en) * 2021-12-20 2023-06-29 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN114292192A (zh) * 2022-01-17 2022-04-08 山东泓瑞医药科技股份公司 一种3,4-二甲氧基苯甲酸甲酯的合成方法
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
EP3788042A4 (de) * 2018-04-29 2022-01-26 BeiGene, Ltd. Bcl-2-inhibitoren
US20220073513A1 (en) * 2018-12-29 2022-03-10 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法

Also Published As

Publication number Publication date
US20230159522A1 (en) 2023-05-25
AU2021256580A1 (en) 2022-09-29
CN116802179A (zh) 2023-09-22
WO2021208963A1 (en) 2021-10-21
MX2022013006A (es) 2023-01-11
IL296582A (en) 2022-11-01
KR20230002419A (ko) 2023-01-05
CA3172478A1 (en) 2021-10-21
EP4136084A4 (de) 2023-11-01
CN116969936A (zh) 2023-10-31
EP4136084A1 (de) 2023-02-22
BR112022019525A2 (pt) 2023-11-14
ZA202209891B (en) 2023-05-31
TW202200574A (zh) 2022-01-01
JP2023520843A (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
CN116969937A (zh) Bcl-2抑制剂
US10233186B2 (en) Inhibitors of activin receptor-like kinase
AU2016311426B2 (en) Compounds and compositions useful for treating disorders related to NTRK
CN109715634B (zh) Menin-mll相互作用的稠合二环抑制剂
WO2019210828A1 (en) Bcl-2 INHIBITORS
TWI408135B (zh) 腎外髓質鉀通道抑制劑
EP3027616B1 (de) Azaindolverbindungen als rorc-modulatoren
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
BRPI0817843B1 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
EA036630B1 (ru) Бициклические производные
CA2922933A1 (en) 2,8-diazaspiro[4.5]decane and 3,9-dispiro[5.5]undecane derivates and pharmaceutical compositions thereof useful as tryptophan hydroxylase inhibitors
JP2011521888A (ja) グレリン受容体の調節因子としてのn−フェニルヒドラジド誘導体
CN113454086A (zh) 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物
WO2016100166A1 (en) SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
WO2008100618A2 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
CA3180803A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
KR20190026917A (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
CN114805311A (zh) 螺环茚
EP4072678A1 (de) Antagonisten des muskarinischen acetylcholinrezeptors m4
EP4055013B1 (de) Wdr5-inhibitoren und modulatoren
AU2021253584A1 (en) Kinase inhibitors
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
KR102614279B1 (ko) 테트라히드로옥세피노피리딘 화합물
WO2023249872A1 (en) Substituted fused bicyclic compounds and related methods of treatment
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination